Pemphigus Therapeutic Development and Pipeline Review H1 2015

DALLAS, March 31, 2015 /PRNewswire/ --

RnRMarketResearch.com adds "Pemphigus - Pipeline Review, H1 2015" therapeutic market research report of 68 pages with latest updates, data and information to its online business intelligence library.

The report "Pemphigus - Pipeline Review, H1 2015" report provides comprehensive information on the therapeutic development for Pemphigus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pemphigus and special features on late-stage and discontinued projects.

Pemphigus is a group of rare autoimmune diseases that cause blistering of the skin and mucous membranes (mouth, nose, throat, eyes, and genitals). The immune system produces antibodies against specific proteins in the skin and mucus membranes. These antibodies break the bonds between skin cells. This leads to the formation of a blister. This most serious form of pemphigus is paraneoplastic pemphigus. Pemphigus vulgaris usually starts in middle-aged and older adults, but is can occur at any age.

Companies discussed in this report include Clinuvel Pharmaceuticals Limited, Genmab A/S, HanAll Biopharma Co., Ltd., Immunomedics, Inc., Momenta Pharmaceuticals, Inc., Novartis AG, PinCell srl. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=314373 . (This is a premium report priced at US$2000 for a single user License.)

Drug Profiles discussed in this report include afamelanotide, Antibody for Autoimmune Disorders and Inflammation, DP-C006, Drugs to Target HSP27 for Autoimmune Disorders, HL-161, ofatumumab, PC-111, VAY-736, veltuzumab and others.

Featured News & Press Releases cover by this report include: Nov 21, 2014: Immunomedics Announces Orphan Drug Designation for Veltuzumab for the Treatment of Pemphigus; Oct 07, 2014: Stiefel, a GSK company, announces start of phase III study of subcutaneous ofatumumab for pemphigus vulgaris; May 22, 2014: Scenesse receives US orphan-drug designation in Hailey-Hailey Disease; May 19, 2014: Afamelanotide 16mg recognised for potential to treat rare Hailey-Hailey Disease; Feb 10, 2014: Phase II study of SCENESSE in rare skin disorder Hailey-Hailey Disease commences; Oct 28, 2013: Positive pilot data published on SCENESSE in rare skin disorder; Jul 04, 2013: Genmab Collaborator GSK Starts New Ofatumumab Phase III Study in Rare Skin Disorder.

Reasons to buy 

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Pemphigus
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Pemphigus pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore more reports on Dermatology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/dermatology-therapeutics .

More reports on Dermatology therapeutics:

Actinic (Solar) Keratosis - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Actinic (Solar) Keratosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Actinic (Solar) Keratosis and special features on late-stage and discontinued projects. Companies discussed in this report include 3M Drug Delivery Systems, Advancell, Biofrontera AG, Clinuvel Pharmaceuticals Limited, Digna Biotech, S.L., Dolorgiet Gmbh & Co. Kg, Foamix Pharmaceuticals Ltd., G&E Herbal Biotechnology Co., Ltd., Galderma S.A., Kinex Pharmaceuticals, LLC, LEO Pharma A/S, Novartis AG, Novelix Pharmaceuticals, Inc., Promius Pharma, LLC, RestorGenex Corporation, Spherium Biomed S.L. Complete report available at http://www.rnrmarketresearch.com/actinic-solar-keratosis-pipeline-review-h1-2015-market-report.html .

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2015 

This report provides comprehensive information on the therapeutic development for Venous Leg Ulcers (Crural ulcer), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies discussed in this report include Adocia, CardioVascular BioTherapeutics, Inc., CoDa Therapeutics, Inc., CytoTools AG, FirstString Research, Inc., Intralytix, Inc., MacroCure Ltd., Pergamum AB, RegeneRx Biopharmaceuticals, Inc., Smith & Nephew Plc, Stratatech Corporation. Complete report available at http://www.rnrmarketresearch.com/venous-leg-ulcers-crural-ulcer-pipeline-review-h1-2015-market-report.html .

About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Contact:
Ritesh Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel:  +1-888-391-5441
[email protected]

SOURCE RnR Market Research

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED